JPRN-UMIN000014902
Completed
Phase 2
A multicenter phase II study for previouly untreated advanced stage peripheral T-cell lymphoma evaluating efficacy and safety of combination chemotherapy with THP-COP regimen - A phase II study of THP-COP therapy for previouly untreated advanced stage peripheral T-cell lymphoma.
Hematological Malignancy Study Group0 sites40 target enrollmentStarted: August 20, 2014Last updated:
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Hematological Malignancy Study Group
- Enrollment
- 40
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional,observational
Eligibility Criteria
- Ages
- 20years-old to 79years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Presence of central nervous involvement (clinical or pathological) 2\.Diabetes mellitus receiving insulin therapy 3\.Uncontrollable hypertension 4\.History of angina pectoris or myocardial infarction. Comorbidity of cardiomyopathy. Arrhythmia on treatment with antiarrhythmic agents 5\.Positive test for HBs antigen 6\.Positive test for HCV antibody 7\.Positive test for HIV antibody 8\.Accompanying interstitial pneumonitis, pulmonary fibrosis or severe emphysema diagnosed by chest X\-ray 9\.Severe infection 10\. Biopsy proven or clinically diagnosed Liver cirrhosis 11\. Active double cancer: overlapping cancer or asynchronous cancer within 5 years. Carcinoma in situ, intramucosal cancers, and other equivalent lesions are not included for the active double cancer 12\. Use of major tranquilizer, antidepressant or antimanic drugs 13\. Severe psychosis
Investigators
Similar Trials
Active, not recruiting
Phase 1
A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-onset Type 1 Diabetes Mellitus (T1D)Recent-onset Type 1 Diabetes mellitus (T1D)MedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2017-002871-24-BEIntrexon T1D Partners, LLC (IT1D)48
Active, not recruiting
Not Applicable
A Phase II Multicenter Study on the Treatment of Adult de novo Philadelphia Chromosome Positive Ph Acute Lymphoblastic Leukemia ALL with the Protein Tyrosine Kinase Inhibitor BMS-354825. - GIMEMA Protocol LAL1205Treatment of Adult de novo Philadelphia Chromosome Positive Ph Acute Lymphoblastic Leukemia ALLMedDRA version: 6.1Level: PTClassification code 10000846EUCTR2005-005107-42-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO48
Active, not recruiting
Not Applicable
A multicenter phase II trial of Recipient pre-treatment with Short-Term Rapamycin for the prevention of acute GVHD after hematopoietic stem cell transplantation in Elderly Patients - NDGraft Versus Host DiseaseMedDRA version: 9.1Level: LLTClassification code 10048396Term: Bone marrow transplant rejectionMedDRA version: 9.1Level: LLTClassification code 10000802Term: Acute GVH diseaseEUCTR2008-002310-22-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Completed
Phase 2
Multicenter Phase II Clinical Study of the research on optimal assessments and treatment strategy of nilotinib in newly diagnosed chronic myelogenous leukemia patients in the chronic phase (CML-CP) based on early achievement of complete molecular response (CMR); N-roadChronic Myelogenous LeukemiaJPRN-UMIN000008565Cooperative study between Jikei University Kashiwa Hospital and Shimousa Hematology Study Group50
Unknown
Phase 2
A phase 2 multicenter clinical study evaluating the safety and efficacy of Nilotinib in patients with Imatinib- resistant/intolerant CML in chronic phaseChronic myelogenous leukemiaJPRN-UMIN000001927Tokyo STI Study Group50